Alpha-glucosidase Therapy Center

In patients with type 2 diabetes, pre-meal treatment with the alpha-glucosidase inhibitor acarbose may help protect against endothelial dysfunction and perhaps future cardiovascular decline due to postprandial hyperglycemia, research suggests.

New Alpha-Glucosidase inhibitor for treatment of postprandial hyperglycemica released in India for the treatment of diabetes.

Researchers say a traditional Indian medicine, Salacia oblonga for treating diabetes lowers blood sugar and insulin levels in a way similar to prescription drugs.

First prospective intervention study testing the postprandial hyperglycemia hypotheses as a risk factor for cardiovascular disease. “Acarbose treatment was associated with a relative risk reduction of 49% for cardiovascular events.

American and Korean red ginseng may help to normalize blood glucose levels and improve insulin secretion and sensitivity in patients with type 2 diabetes.

Learning objectives Upon completion of this chapter, the technician should be able to do the following: 1. Differentiate between Type 1 and Type 2 Diabetes. 2. Explain the Criteria for the diagnosis of Diabetes. 3. Explain Insulin Resistance. 4. Discuss the importance of monitoring blood sugars. 5. Explain the purpose …

Treatment with an alpha-glucosidase inhibitor may be particularly beneficial for patients with type 2 diabetes

Miglitol decreased hunger and increased feelings of satiety after a meal in obese, diabetic patients

IGT and IFG are major risk factors for future diabetes and cardiovascular disease (CVD) and the need for urgent intervention.

Alpha-glucosidase inhibitor Miglitol lowers A1c, postprandial glucose and insulin as monotherapy.